Berthold F, Engelhardt-Fahrner U, Schneider A, Schumacher R, Zieschang J
Children's Hospital, University of Cologne, F.R.G.
In Vivo. 1991 May-Jun;5(3):245-7.
Serum neuron specific enolase (NSE) was determined in 159 patients with neuroblastoma at diagnosis and in 183 children of various age groups. We found an age dependence of reference intervals for NSE and defined the 95th percentiles as upper normal limits. The specificity was 91.3% and the sensitivity 73.0%. The incidence of abnormal NSE levels increased with stage. The NSE serum levels were not influenced by histologic differentiation. Neuron specific enolase proved to be a reliable tumor-marker for monitoring the disease. Moreover, abnormal NSE values at diagnosis were of prognostic significance for patients with localized neuroblastoma (stages I-III) and for children with metastatic disease (stage IV), but not for infants with stage IV S. In comparison to catecholamine metabolite determination neuron specific enolase appeared to be a slightly less specific, equally sensitive tumor marker but with prognostic information for children with neuroblastoma.
在159例神经母细胞瘤患者确诊时测定了血清神经元特异性烯醇化酶(NSE),并在183名不同年龄组的儿童中进行了测定。我们发现NSE参考区间与年龄有关,并将第95百分位数定义为正常上限。特异性为91.3%,敏感性为73.0%。NSE水平异常的发生率随分期增加。NSE血清水平不受组织学分化的影响。神经元特异性烯醇化酶被证明是监测该疾病的可靠肿瘤标志物。此外,确诊时NSE值异常对局限性神经母细胞瘤(I - III期)患者和转移性疾病(IV期)儿童具有预后意义,但对IV - S期婴儿无此意义。与儿茶酚胺代谢物测定相比,神经元特异性烯醇化酶似乎是特异性稍低、敏感性相同的肿瘤标志物,但可为神经母细胞瘤儿童提供预后信息。